KASINGER JAMES R. — SEC insider filings
SEC reporting owner CIK 1708172. 36 insider filings on record with FilingPulse; latest filed 2026-10-28.
Transaction summary — filings shown
Covers all 36 filings on record, filed 2020-10-06 to 2026-10-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 22 legs across 15 filings — 79,192 shares, $8,506,391 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 90.
- Largest priced transaction: sale of 8,997 shares @ $205.60 ($1,849,783) in CRISPR Therapeutics AG, filed 2021-01-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | General Counsel and Secretary | 36 | — | 22 legs · 79,192 sh · $8,506,391 | 90 |
Insider filings — KASINGER JAMES R.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-28 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 18,000 (derivative) @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-10-15 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 2,113 · Sale (S): 1,040 @ $49.26 · Option exercise (M): 2,113 (derivative) | EDGAR |
| 2026-10-08 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 1,990 @ $13.62 · Sale (S): 1,990 @ $60.04 · Option exercise (M): 1,990 (derivative) @ $0 | EDGAR |
| 2026-09-24 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 10,400 @ $13.62 · Sale (S): 10,400 @ $60.24 · Option exercise (M): 10,400 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 6,250 · Sale (S): 3,182 @ $46.78 · Grant/award (A): 38,499 (derivative) @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Option exercise (M): 6,250 (derivative) | EDGAR |
| 2026-03-17 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 6,875 · Sale (S): 3,450 @ $48.26 · Option exercise (M): 6,875 (derivative) | EDGAR |
| 2026-03-12 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 5,500 · Sale (S): 2,800 @ $52.80 · Option exercise (M): 5,500 (derivative) | EDGAR |
| 2026-02-20 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 3,825 · Sale (S): 2,112 @ $52.58 · Option exercise (M): 3,825 (derivative) | EDGAR |
| 2025-10-15 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 2,114 · Sale (S): 1,076 @ $66.60 · Option exercise (M): 2,114 (derivative) | EDGAR |
| 2025-10-03 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-03-24 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 6,250 · Sale (S): 3,185 @ $41.23 · Option exercise (M): 6,250 (derivative) | EDGAR |
| 2025-03-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 36,666 (derivative) @ $0 · Grant/award (A): 27,500 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 5,500 · Sale (S): 2,850 @ $42.42 · Option exercise (M): 2,250 · Sale (S): 1,116 @ $43.32 · Option exercise (M): 5,500 (derivative) · Option exercise (M): 2,250 (derivative) | EDGAR |
| 2025-02-19 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 20,000 · Sale (S): 9,595 @ $53.85 · Option exercise (M): 3,825 · Sale (S): 1,947 @ $52.80 · Option exercise (M): 20,000 (derivative) · Option exercise (M): 3,825 (derivative) | EDGAR |
| 2024-10-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 18,333 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 2,113 · Sale (S): 1,089 @ $46.28 · Option exercise (M): 2,113 (derivative) | EDGAR |
| 2024-03-22 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 33,333 (derivative) @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-12 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 5,500 · Sale (S): 2,801 @ $78.26 · Option exercise (M): 2,250 · Sale (S): 1,146 @ $74.44 · Option exercise (M): 5,500 (derivative) · Option exercise (M): 2,250 (derivative) | EDGAR |
| 2024-02-21 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 3,825 · Sale (S): 1,913 @ $79.67 · Option exercise (M): 3,825 (derivative) | EDGAR |
| 2023-10-17 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 16,667 (derivative) @ $0 · Grant/award (A): 6,340 (derivative) @ $0 | EDGAR |
| 2023-03-14 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 2,833 · Tax withholding (F): 1,283 @ $43.22 · Option exercise (M): 2,250 · Tax withholding (F): 1,022 @ $43.22 · Option exercise (M): 2,833 (derivative) · Grant/award (A): 40,000 (derivative) @ $0 · +2 more | EDGAR |
| 2023-02-22 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 3,825 · Tax withholding (F): 1,950 @ $48.26 · Option exercise (M): 3,825 (derivative) | EDGAR |
| 2022-12-06 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 6,667 · Tax withholding (F): 3,234 @ $52.26 · Option exercise (M): 6,667 (derivative) | EDGAR |
| 2022-10-12 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2022-08-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 2,834 · Tax withholding (F): 1,321 @ $62.56 · Option exercise (M): 2,250 · Tax withholding (F): 1,039 @ $61.08 · Option exercise (M): 2,834 (derivative) · Option exercise (M): 2,250 (derivative) | EDGAR |
| 2022-02-22 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 34,200 (derivative) @ $0 · Grant/award (A): 15,300 (derivative) @ $0 | EDGAR |
| 2021-12-07 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 13,333 · Tax withholding (F): 6,303 @ $69.17 · Option exercise (M): 13,333 (derivative) | EDGAR |
| 2021-12-03 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 7,342 @ $13.62 · Option exercise (M): 7,342 (derivative) @ $0 | EDGAR |
| 2021-10-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 10,800 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 10,000 · Tax withholding (F): 4,741 @ $117.86 · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2021-03-12 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 2,833 · Tax withholding (F): 1,353 @ $124.15 · Grant/award (A): 25,360 (derivative) @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2021-01-20 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 27,500 @ $51.49 · Sale (S): 6,785 @ $203.58 · Sale (S): 7,818 @ $204.40 · Sale (S): 8,997 @ $205.60 · Sale (S): 1,800 @ $206.05 · Sale (S): 2,100 @ $207.61 · +1 more | EDGAR |
| 2020-12-10 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 22,026 @ $13.62 · Option exercise (M): 22,026 (derivative) @ $0 | EDGAR |
| 2020-10-06 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 11,666 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1708172 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs